GlassScriptPhysician profile
Amit V Patel
NPI 1134417660
$4,064.47
in general payments reported to CMS, 2019-2025
28 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,607 · 2020: $28.61 · 2021: $51.72 · 2022: $113 · 2023: $204 · 2024: $607 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,395.53 | 2019-2025 | |
| Sandoz INC. | $189.64 | 2024 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $182.42 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $153.61 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare LLC | $117.53 | 2025 | |
| Celgene Corporation | $103.62 | 2023-2024 | Camzyos |
| Janssen Biotech, INC. | $99.99 | 2022 | |
| Lilly USA, LLC | $96.32 | 2019 | |
| Edwards Lifesciences Corporation | $83.86 | 2024-2025 | Carpentier-Edwards Physio II Annuloplasty Ring |
| Heartflow, INC. | $66.21 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $63.34 | 2024 | |
| Impulse Dynamics (USA) INC. | $59.83 | 2023-2024 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $52.75 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $50.83 | 2023-2024 | Dupixent |
| Janssen Pharmaceuticals, INC | $45.88 | 2020-2023 | Xarelto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.63 | 2019-2025 | Jardiance |
| Welch Allyn | $32.18 | 2021 | |
| Novo Nordisk INC | $28.66 | 2025 | Wegovy |
| Bridgebio Pharma, INC. | $23.21 | 2025 | Attruby |
| Pfizer INC. | $22.87 | 2025 | |
| Irhythm Technologies, INC. | $22.59 | 2023 | Zio Xt Patch |
| Medtronic, INC. | $22.26 | 2025 | Corevalve Evolut R |
| Genentech USA, INC. | $19.74 | 2023 | Actemra |
| Cardiovascular Systems INC. | $19.54 | 2021 | |
| Esperion Therapeutics, INC. | $19.36 | 2025 | Nexletol |
| Boston Scientific Corporation | $19.27 | 2024 | Watchman Flx |
| Cardiva Medical, INC. | $16.32 | 2025 | Cardiva Vascade 6/7f Vcs |
| Amneal Pharmaceuticals LLC | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.